- Home
- HHS vs THTX Comparison
HHS vs THTX Comparison
Compare HHS & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- THTX
- Stock Information
- Founded
- HHS 1923
- THTX 1993
- Country
- HHS United States
- THTX Canada
- Employees
- HHS N/A
- THTX N/A
- Industry
- HHS Advertising
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- THTX Health Care
- Exchange
- HHS Nasdaq
- THTX Nasdaq
- Market Cap
- HHS 52.3M
- THTX 56.1M
- IPO Year
- HHS N/A
- THTX N/A
- Fundamental
- Price
- HHS $6.97
- THTX $1.21
- Analyst Decision
- HHS
- THTX Hold
- Analyst Count
- HHS 0
- THTX 1
- Target Price
- HHS N/A
- THTX N/A
- AVG Volume (30 Days)
- HHS 13.5K
- THTX 31.8K
- Earning Date
- HHS 11-14-2024
- THTX 10-10-2024
- Dividend Yield
- HHS N/A
- THTX N/A
- EPS Growth
- HHS N/A
- THTX N/A
- EPS
- HHS N/A
- THTX N/A
- Revenue
- HHS $187,093,000.00
- THTX $84,316,000.00
- Revenue This Year
- HHS N/A
- THTX $5.60
- Revenue Next Year
- HHS $4.05
- THTX $4.62
- P/E Ratio
- HHS N/A
- THTX N/A
- Revenue Growth
- HHS N/A
- THTX 5.75
- 52 Week Low
- HHS $6.45
- THTX $1.08
- 52 Week High
- HHS $8.87
- THTX $2.58
- Technical
- Relative Strength Index (RSI)
- HHS 34.77
- THTX 43.96
- Support Level
- HHS $6.90
- THTX $1.21
- Resistance Level
- HHS $7.26
- THTX $1.47
- Average True Range (ATR)
- HHS 0.23
- THTX 0.07
- MACD
- HHS -0.03
- THTX -0.00
- Stochastic Oscillator
- HHS 4.23
- THTX 18.75
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.